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A B S T R A C T
In non-cancerous cells, transforming growth factor-b (TGFb) regulates cellular responses primarily
through Smad signaling. However, during cancer progression (including colorectal) TGFb promotes
tumoral growth via Smad-independent mechanisms and is involved in crosstalk with various pathways
like the mitogen-activated protein kinases (MAPK) and Wnt. Crosstalk between these pathways
following activation by TGFb and subsequent downstream signaling activity can be referred to as a
crosstalk signaling signature. This review highlights the progress in understanding TGFb signaling
crosstalk involving variousMAPK pathwaymembers (e.g., extracellular signal-regulated kinase (Erk) 1/2,
Ras, c-Jun N-terminal kinases (JNK) and p38) and the Wnt signaling pathway.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Globally, colorectal cancer (CRC) was the third most commonly
diagnosed cancer in 2012 with over 1.36 million new cases (9.7% of
all cancers). Then, it led to almost 694,000 deaths (i.e., 8.5% of all
cancer deaths) [1]. Australia and New Zealand have one of the
highest incidence rates globally (44.8 and 32.2 per 100,000 in men
and women respectively), whilst the lowest rates are found in
Middle Africa (4.5 and 3.5 respectively per 100,000 in men and
women respectively) [1].
Diagnostically, various staging systems have been developed to
describe progression of the severity of the disease (e.g., TNM
ClassiﬁcationofMalignantTumours,AustralianClinico-pathological
Staging (ACPS) System [2] and Dukes’ staging system [3]). These
staging tools, usually obtained from patho-histological analyses of
CRCbiopsies, help clinical oncologists to assess size, location and the
spread of the cancerous lesion to other parts of the body and aid in
patient treatment andmanagement. Many studies have shown that
CRC survival rates primarily dependent on howadvanced the cancer
is at initial diagnosis. Despite the availability of numerous screening
strategies (Table 1) aggressive surgical therapies and extensive
research on the genomic, molecular and cellular basis of CRC,
detection at the earliest stages remains elusive.
If detected early, CRC is associated with excellent 5-year
survival (>90%) following simple (often curative) surgical resec-
tion, while patients diagnosed with later stage cancers (ACPS or
Dukes’ C or D) experience recurrence and distant metastases
leading to particularly poor 5-year survival rates of less than 10%
[4]. This progressive decrease in survival rates between early to late
stage CRCs (90–10%) has been shown to be associated with the
disruption of a number of well-established signaling pathways
(Supplementary Table 1). These include, but are not limited to,
transforming growth factor-beta (TGFb)-Smad signaling, mitogen-
activated protein kinase (MAPK) signaling pathways and Wnt
signaling. This review will brieﬂy discuss TGFb ligands, their
receptors, TGFb canonical signaling through Smads and will
highlight recent ﬁndings concerning its role/s in CRC and
extensively focusing on the signaling crosstalk of TGFb with the
above-mentioned pathways. TGFb, or proteins in associated
pathways, could be used as early detection biomarkers that
may, in the long term, improve survival and management of the
global CRC health burden. A list of potential early detection
biomarkers for CRC is provided in Table 2.
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2. TGFb superfamily ligands
The TGFb superfamily consists of a large family of secreted
cytokines that regulate a multitude of cellular functions and
disease pathogenesis. The superfamily is divided into three major
subfamilies; TGFb, activin/inhibin/nodal branches and BMP/GDF
(bone morphogenetic proteins/growth differentiation factors), all
of whompossess diverse and complementary physiological effects.
The TGFb subfamily members, named for their cell transforming
activities (i.e., cell growth and differentiation) from in vitro assays
are now unequivocally known to be involved in both tumor
suppression and tumor progression (i.e., proliferation, invasion
and metastases). Activin and inhibins are well known positive and
negative regulators of follicle-stimulating hormone respectively
[17]. Nodal along with LEFTY-1 and LEFTY-2 is required for
formation of mesoderm and axial patterning during embryonic
development [18,19]. The GDF and BMP subfamily proteins have
major roles in skeletal development [20], neurogenesis [21], and
regulation of ovarian folliculogenesis [22].
The bona ﬁde TGFb subfamily consists of three TGFb isoforms,
TGFb1, TGFb2 and TGFb3 encoded by three different genes located
on different chromosomes (19q13.1, 1q41 and 14q24 respectively)
but which are thought to function through the same receptor
signaling systems. All TGFb ligands are produced and secreted in
vivo as ‘latent’ inactive zymogen complexes containing a mature
TGFb dimer in a non-covalent complex with latency associated
peptides (LAP) that are bound to their respective latent TGFb
binding proteins [23]. The LAP domain ensures that ‘inadvertent’
release of TGFb does not occur in normal cells under normal
physiological conditions. Latent TGFb can be activated in vivo
through a variety of mechanisms. These include activation either
by proteases (e.g., plasmin) [24] and/or various matrix metal-
loproteinases (MMP-2 and MMP-9) [25] by cleavage of the LAP.
Alternatively, conformational changes in the LAP mediated by
integrins avb6 [26], avb8 [27], and thrombospondin-1 [28] allow
the release of active TGFb1 from its associated LAP. The activation
of TGFb1 by integrin avb6 is restricted to epithelial tissues as
avb6 is only expressed in those cells. Equally, the expression of
TSP-1 in some epithelial tissues suggests the possibility that
avb6 and TSP-1may operate in tandem to activate latent TGFb1. A
recent study has shown that methylation of the TSP-1 gene results
in suppression of TGFb1 activation in CRC [29]. Integrin avb8-
mediated activation, however, depends on the presence of
MT1-MMP (MMP-14) [27]. It is therefore clear that TGFb1 can
be activated via a number of different mechanisms and in various
cellular contexts. These allow it to play an important role in
different cellular contexts and functions. As such, it is not
surprising that alterations in plasmin or plasminogen binding
[30] and alterations in expression of MMP-2 and MMP-9 [31],
integrin avb6 [32] and active TGFb1 [33] have been found
collectively to be associated with poor CRC prognosis and
subsequently poor survival.
3. TGFb receptors
The TGFb receptors were identiﬁed by methods involving
afﬁnity labeling of cells with radio-iodinated TGFb (125I-TGFb)
ligand and subsequent mapping of receptors to which this bound.
Three different receptors, namely type I (53kDa), type II
(73–95kDa) and type III (110kDa) were identiﬁed depending on
their molecular weights [58]. The type I and type II receptors were
found to contain serine/threonine kinase domains and activity,
Table 1
Currently available/emerging CRC screening strategies, ns: not speciﬁed.
Test Sensitivity
(%)
Speciﬁcity
(%)
Frequency Year
developed
Comments Ref.
Traditional assays
Colonoscopy >95 95–99 Every
10 years
from age 50
1969 The current gold standard, but invasive, expensive and requires bowel
preparation
[5]
Sigmoidoscopy 98–100 35–70 5 years 1976 Only screens the distal colon and rectum [6]
Double contrast
barium enema
(DCBE)
45 90 5 years 1920s–1930s Detects only 30–50% of tumors detected by colonoscopy. Recommended only if
endoscopic screening options are not available.
[7]
Computed
tomography (CT)
colonography
90 86 5 years 1994 Becoming accepted as an alternative to colonoscopy. [8]
Guaiac fecal occult
blood test
(GFOBT)
16–38 98–99 Yearly 1967 Detects traces of blood released frombowel cancers or their precursors (polyps or
adenomas) into the stool. Results may be affected by consumption of red meat
and vitamin C. All positive FOBT tests are often followed up with colonoscopy.
[9]
Fecal
immunochemical
test (FIT)
56–89 91–98 Yearly 1978 Speciﬁc antibodies are used against the globin component of hemoglobin.
Unaffected by dietary intake, but the epitope may be destroyed by bacterial
enzymes in the stool giving false negatives
[9]
Fecal DNA 52–91 93–97 3 years 2003 Identiﬁes genetic alterations involved in adenoma-carcinoma progression.
ColoSureTM test, for example, detects methylation of the vimentin gene, an
epigenetic marker.
[10]
Carcinoembryonic
antigen (CEA)
43 90 ns 1969 Not suitable for routine detection, but useful for monitoring recurrence. [11]
Emerging assays
Colon capsule
endoscopy (CCE)
>80 64–95 ns 2006 A non-invasive technique in which a capsule containing a wireless camera is
swallowed and transmits images of the inside of the digestive tract to an
extracorporeal monitor. Second generation colon capsule endoscopy has a
diagnostic sensitivity of 89% or higher to identify polyps >5mm.
[12,13]
MicroRNA 50–90 >70 ns 2009 miR92 reported as elevated in the plasma of CRC patients comparedwith controls [14,15]
Blood RNA
(ColonSentry)
72 70 Anytime 2008 Blood-based test which measures the RNA of seven-gene biomarker panel
(ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, VNN1 and IL2RB) extracted from
peripheral blood cells
[16]
SEPT9 67–96 81–99 ns 2008 Blood-based test which measures the methylated SEPT9 DNA in plasma [16]
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whilst the type III receptors lacked any similar domain [59]. The
detailed structure of these three receptors is illustrated in Fig. 1.
3.1. TGFb type III receptors
The transforming growth factor type III receptor (TGFbR3)
betaglycan is the most ubiquitously expressed type III receptor.
Betaglycan acts as an accessory receptor by presenting TGFb
ligands to the type II receptors and promoting signaling [60]. The
short cytoplasmic tail of betaglycan consists of a class I PDZ
binding motif that binds to GAIP-interacting protein C-terminus
(GIPC). GIPC interaction with betaglycan increases the stability of
betaglycan at the cell surface and promotes TGFb1 and
TGFb2 mediated gene expression in Mv1Lu mink lung epithelial
and L6 myoblast cells [61]. More recently the GIPC-betaglycan
interaction has been shown to inhibit TGFb-mediated
Smad signaling and migration in breast cancer cells. However,
the exact mechanism/s by which this occurs has yet to be
characterized [62].
3.2. TGFb type II receptor
Transforming growth factor type II receptor (TGFbR2) is a
transmembrane serine/threonine kinase receptor with a signal
peptide, a cysteine-rich N-glycosylated extracellular domain, a
transmembrane domain, and a cytoplasmic serine/threonine
kinase domain ﬂanked by a short juxtamembrane domain and
C-terminal tail [63]. TGFbR2 can bind to all three TGFb ligands, but
cannot participate in downstream signaling in the absence of
TGFbR1. The presence of betaglycan is also essential to facilitate
high afﬁnity TGFb binding to TGFbR2 which then participates in
downstream signaling. As yet, only TGFbs are known to bind to
TGFbR2 in any extracellular context.
3.3. TGFb type I receptor
Transforming growth factor type I receptor (TGFbR1) is also a
transmembrane serine/threonine kinase receptor and closely
resembles TGFbR2 in structure. TGFbR1 contains a signal peptide,
Table 2
Potential early detection biomarkers for CRC. nd: not determined.a
Candidate biomarker Sample type Mechanism of
identiﬁcation
Can discriminate Sensitivity
(%)
Speciﬁcity
(%)
Ref.
Individual biomarkers
Alpha 1-antitrypsin Serum Protein expression
levels
87 73 [34]
Amphiregulin Blood/serum Protein expression
levels
Controls from Dukes’ A CRC nd nd [35]
CEA Blood/serum Protein expression
levels
Controls from Dukes’ A–D
stage CRCs
53 93 [34–
37]
CXCL11 Blood/serum Protein expression
levels
Controls from Dukes’ A CRC nd nd [35]
CXCL5 Blood/serum Protein expression
levels
Controls from Dukes’ A CRC nd nd [35,38]
IL6 Blood/serum Protein expression
levels
27 95 [35]
IL8 Blood/serum Protein, mRNA
expression levels
Controls from Dukes’ A CRC 30 95 [35,39]
Methylated Septin 9 (SEPT9) Blood DNA methylation 67–96 81–99 [40–
44]
MMP7 Serum mRNA expression
levels
58 100 [34]
Suppressor of cytokine signalling (SOCS) 2 and SOCS6 Tumors Protein expression
levels
nd nd [45]
uPAR Serum mRNA expression
levels
nd nd [34]
Collagen type X alpha1 (CPL10A1) Serum Protein expression
levels
Controls from Adenoma and
colon cancer
63 85 [46]
Metastasis associated in colon cancer 1 (MACC1) Tumor samples Protein expression
levels
nd nd [47]
Biomarker panels
Tumor associated monocyte genetic ﬁnger print Blood monocyte
samples
Gene expression 92.6 92.3 [48]
IGFBP2, DKK3 and PKM2 Blood Protein expression
levels
73 95 [49]
BMP3, NDRG4, VIM, TFPI2 and a mutant KRAS Stool DNA methylation Cancer from controls 68–86 77–92 [50–
53]
Adenoma (size >1 cm) to
controls
52–73 85–92
Adenoma (size 1 cm) to
controls
45–62 85–92
miR-19a-3p, miR-223-3p, miR-92a-3p and miR-422a Serum mRNA expression
levels
84.3 91.6 [54]
miR-601 and miR-760 Plasma mRNA expression
levels
CRC to normal controls 83.3 69.1 [55]
Adenomas to normal
controls
72.1 62.1 [55]
miR-532-3p, miR-331, miR-195, miR-17, miR-142-3p, miR-
15b, miR-532, and miR-652
Plasma mRNA expression
levels
Polyps from controls 88 64 [56]
a The data presented in this table only summarises biomarkers from research published in the last 5–6 years. For amore detailed reviewon this topic please see “Biomarkers
for Early detection of Colorectal Cancer and Polyps: Systematic Review” by Shah et al. [57].
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a cysteine-rich N-glycosylated extracellular domain, a cytoplasmic
kinase region with 41% sequence homology to TGFbR2 and a very
short C-terminal tail [64]. A unique feature of TGFbR1 is its highly
conserved 30 amino acid region preceding the cytoplasmic kinase
region that is called the GS domain because of the characteristic
SGSGSG sequence it contains. Ligand-induced phosphorylation of
serine and/or threonine residues in the GS region is required for
signaling. TGFbR1 forms a heterodimer with TGFbR2 and this
complex collectively takes part in TGFb-mediated downstream
signaling [64].
4. Canonical signaling of TGFb receptors through Smads
Intracellular TGFb signaling is complex and affects various
cellular functions, both directly and indirectly. A well-character-
ized signaling pathway that is initiated by active heterodimeric
TGFb receptors is through Smads, although Smad-independent
TGFb signaling pathways are also known to exist [65]. TGFb
signaling via Smads is facilitated by TGFbR1 and TGFbR2, which
form both homodimeric and heterodimeric complexes required for
signaling. Dysfunction in one or more components of the
functional TGFb complex has been associated with cancers
(including CRC) and these are brieﬂy discussed later in this review.
Canonical Smad signaling (Fig. 2) is initiated by preferential
binding of active TGFb1 to TGFbR2 that then recruits, binds and
transphosphorylatesTGFbR1intheGSregion, inducingproteinkinase
activity.ActiveTGFbR1thenphosphorylatesSmad2andSmad3which
form a complexwith Smad4 and translocate to the nucleus, where in
combination with various DNA-binding co-activators, co-repressors
and transcriptionfactors, they regulateexpressionof TGFb responsive
genes [66]. The Smad2/3/4 complex induces expression of the cyclin-
dependentkinase inhibitorp21,whichthen leads tocellgrowtharrest.
Puzzlingly, Smad4 can only translocate into the nucleus when bound
to receptor Smads (Smad1/2/3/5/8) whilst Smad2 and Smad3 can
translocate into the nucleus in a Smad4-independent manner [67]
implying a regulatory role for Smad4 rather than a simple signal
transmission from cytoplasm to nucleus. Studies on various tumor
cells suggest that TGFb-mediated cell migration is not always
dependent on Smad signaling, but also the activation of various
mitogen-activated protein kinases (MAPK) and Rho GTPases that can
be activated by non-canonical Wnt signaling pathways.
5. Non-canonical signaling of TGFb receptors
Increasing evidence over the past few years has revealed that
the complexity of TGFb signaling responses is inﬂuenced not only
[(Fig._1)TD$FIG]
Fig. 1. Structure of TGFb receptors type I (TGFbR1), type II (TGFbR 2) and type III (TGFbR3).
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by core pathway components including ligands, receptors, Smads
and Smad-dependent transcription factors, but also by the ability
of TGFb receptors to activate other Smad-independent (i.e., non-
canonical) pathways through crosstalk resulting in downstream
cellular responses. The mechanisms of crosstalk include, but are
not restricted to, regulation of co-activators and co-repressors
recruited during the process of transcription, regulation of receptor
Smads activity through the mitogen-activated protein kinase
(MAPK) pathway, regulation of inhibitory (I)-Smads (Smad6,7)
expression and other interactions that could activate or inhibit
certainmolecules in the pathways [68]. A few pathways associated
with TGFb signaling crosstalk in CRC and other cancers include, but
are not limited to, MAPK pathways [69] like extracellular signal-
regulated kinase (Erk) 1/2 [70], Ras [70], p38 MAPK and c-Jun
N-terminal kinases (JNKs), phosphoinositol-3-kinase (PI3K), pro-
tein phosphatase 2A (PP2A), Wnt [71] and RhoA [72]. This review
speciﬁcally focuses on MAPK and Wnt signaling pathways.
5.1. Mitogen-activated protein kinase (MAPK) cascades
The MAPK cascades are key membrane-to-nucleus signaling
modules that respond to various stimuli resulting in the
phosphorylation and activation of transcription factors required
for gene expression [69]. Downstream activation of distinct MAPK
pathways of Erk1/2, stress-activated protein kinases (SAPK)/JNK,
Ras and p38 MAPK can be regulated by TGFb1 in either a slow or a
rapid manner. Slow activation (15min) of these pathways is
mediated by Smad-dependent responses whilst the rapid activa-
tion is thought to be mediated by Smad-independent responses
[73]. It has been shown that TGFb has the potential to rapidly
(within 3–6min) activate Erk and Ras MAPK pathways [74]. Rapid
activation of Ras by TGFb in epithelial cells resulted in increased
activity of TGFb-induced Erk MAPK signaling leading to increased
invasion and metastasis [74]. The aberrant activation of MAPK
pathways by TGFb may therefore play a key role in diverting the
TGFb response towards pro-oncogenic outcomes by promoting
invasion and metastasis in CRC.
5.1.1. Erk MAPK pathway
The Erk 1/2 pathway is traditionally known to promote cell
growth and survival [75], but under certain conditions it can have a
pro-apoptotic effects. The Erk pathway is dysregulated in one-third
of all human cancers [76] and is involved in pathogenesis, disease
progression, and oncogenic behavior [77,78]. During late tumouri-
genesis, the activation of both Erk and Ras pathways is required for
TGFb-induced epithelial mesenchymal transition (EMT) leading to
cancer progression [79,80].
The Erk/MAPK signaling cascade can be activated by a wide
range of effectors including peptide growth factors involved in cell
growth and differentiation and integrins [81,82]. Rapid activation
of Erk mediated by TGFb has been observed in epithelial cells,
breast cancer cells and ﬁbroblasts [83]. Smad-dependent delayed
activation of Erk by TGFb is partly accounted for, but does not
completely explain the rapid activation of Erk (within 3–6min) by
[(Fig._2)TD$FIG]
Fig. 2. Outlines the (A) Smad dependent TGFb pathway. Latent TGFb is activated through cleavage of LAP by plasmin or by conformational change induced by integrinavb6.
TGFbR3 presents the active TGFb to phosphorylated TGFbR2which recruits, binds and phosphorylates TGFbR1. The active TGFbR1 phosphorylates Smad2 and Smad3. Active
Smad2 and Smad3 form a complex with Smad 4 (Smad2/3/4) and translocate into the nucleus, where in combination with various DNA-binding co-activators, co-repressors
and transcription factors regulate the expression of TGFb target genes. Smad6 can inhibit the formation of Smad2/3/4 complex and Smad7 can inhibit the Smad2/3 interaction
with TGFbR1 thereby preventing TGFb associated Smad signaling. (B) Ras/Erk non-Smad pathway. The phosphorylated TGFbR1 and TGFbR2 recruit and phosphorylate ShcA
which associated with Grb2/Sos to activate Erk through Ras, Raf andMEK1/2. Erk then regulates downstream transcription factors to control the EMT. (C) JNK/p38 non-Smad
pathway. TGFb receptors interact with polyubiquitinated TRAF6 which recruit TAK1 to activate JNK and p38 pathways via MKK4 and MKK3/6 respectively. Active JNK/p38
then regulate the EMT by controlling the downstream transcription factors. (D) Wnt pathway interactions. Smad7 and APC-Axin-GSKb3 complex interact which other to
either enhance or suppress the activity of Smads. The APC-Axin-GSKb3 complex can activateb-catenin and blocks its inhibitors Twist, Zeb and Snail. Dvl/Dsh can control two
important criteria for the EMT—actin cytoskeletal modiﬁcations and cell adhesion through activation of Rho and Rac1 pathways. Rac1 then activates JNK pathway to further
contribute to the EMT.
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TGFb [65]. There is evidence that TGFbR1 directly participates in
the activation of Erk by recruiting and phosphorylating Src
Homology 2 Domain-Containing) Transforming Protein 1 (ShcA)
on its serine and tyrosine residues. The phosphorylated ShcA then
associates with TGFbR1 via its phosphotyrosine-binding domain
and recruits growth factor receptor binding protein 2 (Grb2) and
Sos proteins, leading to activation of Erk and Ras MAPK pathways
[84,85] (Fig. 2). Erk and Ras then regulate target gene transcription
through their downstream transcription factors and Smads to
control the EMT [84].
Treatment of TGFb-sensitive (Hs578T) and TGFb-responsive
(MDA-MB-231) breast cancer cells with TGFb resulted in different
levels of phosphorylation of Erk 2 downstream to Erk 1. TGFb-
sensitive cells showed a signiﬁcant increase in phosphorylation
within 5min of treatment as compared to the TGFb-responsive
cells, suggesting that the kinetics of Erk phosphorylation induced
by TGFb may vary with cell type and/or physiological state of the
cell [83]. Interestingly, a recent study by Hough et al. [86]
demonstrated that TGFbR-mediated Erk phosphorylation can be
cell type speciﬁc, occurring in phenotypically normal mesenchy-
mal cells but not in the epithelial cell phenotype. This could help to
explain the dysregulated activation of Erk by TGFb observed in
epithelial cancers as they are at various stages of the epithelial–
mesenchymal transition. The TGFb-mediated phosphorylation of
Erk, however, was inhibited when a speciﬁc PI3K-inhibitor,
LY294002, was added. Similar inhibition was observed with the
use of the MEK1/2 inhibitor U0126, suggesting that both
MEK1/2 and PI3K are required for TGFb-mediated Erk activation
[86]. Hough et al. then applied smallmolecule inhibitors to observe
their effect on the activation of the downstream PI3K-activated
pathways, Akt and Erk. They found that both pathways were
activated through TGFb by PI3K, though only Erk phosphorylation
was sensitive (understandably) to inhibition by the
MEK1/2 inhibitor U0126 [86]. Hough et al. also proposed that
TGFb-mediated Erk phosphorylation primarily follows the
PI3K/Pak2/c-Raf/MEK/Erk pathway, supported by a secondary
contribution from Ras, although at a greatly reduced level.
Furthermore, Erk is known to phosphorylate serine or threonine
residues in the PX(S/T)P or (S/T)P motif of the linker regions in
receptor Smads (Smad1,2,3,5,8) which cannot migrate into the
nucleus, thus inhibiting TGFb-Smad signaling [87]. Phosphoryla-
tion of the Smad2 linker regionwas found to be dependent onMEK
activation, which could be increased with the rapid activation of
Erk by epidermal growth factor (EGF), highlighting a direct
functional connection between Erk and the Smad pathway [86].
Erk induced phosphorylation of the linker region of nuclear Smads
and increased the duration of Smad-targeted gene transcription by
extending the half-life of C-terminal pSmad2/3 (Ser465/467). A
thymidine incorporation assay examining the biological conse-
quences of TGFb-mediated activation of Erk, showed a 6-fold
increase in DNA synthesis with TGFb treatment that was
attenuated with MEK1/2 inhibition [86].
The TGFbRs also play an important role in the Erk-TGFb
crosstalk. Primarily, the expression levels and the ratio of TGFbR2/
TGFbR1 hetero-oligomers contribute to different downstream
signalingmodules [88]. Bandyopadhyay et al. have established that
dermal cells with high TGFbR2 expression selectively activate
Erk1/2 [89]. In contrast, epidermal cells with high
TGFbR1 expression favor canonical TGFbR1-Smad signaling and
do not activate Erk. These two ﬁndings highlight the inﬂuence of
TGFbR expression on TGFb-mediated Erk signaling. In the context
of cancer, the crosstalk between Erk, TGFbRs and Smads has been
shown to directly and indirectly promote cancer growth in the
early stages of cancer resulting in metastasis [90–92]. It is also
important to note the tyrosine kinase activity of TGFbR1 as well as
its serine/threonine kinase activity could be a key to understand
the broad spectrum of TGFbR associated signaling in cancer
progression.
5.1.2. Ras MAPK signaling
The Ras proteins play a key role in regulating several aspects of
both normal cell growth and malignant transformation in cancer
signaling. The Ras pathway is deregulated in up to about 30% of
tumors [93]. Chaiyapan et al. reported that mutation of K-Ras
oncogene occurred in 25–35% of CRCs at early stages of progression
[94]. Abnormal activation of Ras leads to increased proliferation
and reduced apoptosis, promoting progression. Similar to Erk,
TGFb-mediated activation of Ras occurs through the ShcA/Grb2/
Sos complex as described earlier [84] (Fig. 2). The rapid activation
of Ras, within (3–6min) by TGFb1 and TGFb2 during CRC
tumourigenesis causes an imbalance between Erk and JNK [74].
Ras family proteins are also known to contribute to this imbalance
by suppressing JNK activation through active K-Ras or by
enhancing Erk activation through H-Ras [95]. Hartsough et al.
have shown that Ras activation is required for TGFb-mediated
Erk1 activation and partially required for growth inhibitory effects
[96]. TGFb growth inhibitory responses in prostate cancer and CRC
cells are transmuted to Smad-independent mitogenic responses in
the presence of active Ha-Ras and Ki-Ras [97,98], whereby active
Ras can induce and enhance the expression of TGFb1, which
explains the frequently observed high levels of active
TGFb1 during cancer [99].
It is known that most TGFb responses are dependent on
cellular context partly due to Smad interactions with cell type
speciﬁc transcription factors. For instance, active Smad3 co-
occupies the genome with Oct4 in human embryonic stem cells,
Myod1 in myotubes and PU.1 in pro-B cells [100]. The
association between Smad2/3 and transcriptional cofactors
can be regulated by the Ras MAPK pathway. Smad2/3 and
tumor suppressor protein p53 can directly interact and together
regulate several TGFb target genes. Overexpression of p53 in
Xenopus animal cap cells showed increased cooperation between
endogenous Smads to induce mesoderm markers [101]. This
cooperation was lost when the animal cap cells were treated
with ﬁbroblast growth factor (FGF)-receptor inhibitor SU5402,
indicating a relationship between p53 and FGF. Treatment with
FGFefﬁciently promoted association of p53 and TGFb-activated
Smad2 [101]. In this mechanism, FGF signals through Ras to
regulate phosphorylation of p53 at its N-terminus, which then
interacts with activated Smad2/3 to regulate TGFb-mediated
tumor suppression [101]. SW480.7 colon cancer cells deﬁcient in
Smad4 having hyperactive Ras signaling do not show TGFb-
mediated antiproliferative responses, as hyperactive Ras inhibits
the function of Smad2/3 by phosphorylating them on their linker
regions [102]
During their study of mammary epithelial cells, Oft et al.
showed that Ras and TGFb1 are required to work in collaboration
to transform benign epithelial cells to induce invasive and
metastatic phenotypes [103]. Results from a recent study by
Kim et al., clearly support this outcome, demonstrating that Ras
expression promoted mesenchymal morphology. Employing nor-
mal MCF-10A cells and MCF-10A/Hras cells which express pro-
oncogenic H-Ras, they showed increased invasive potential with
TGFb treatment that was exacerbated when H-Ras was expressed
[104]. RT-PCR analysis showed that leukotriene B4 receptor-2
(BLT2) expressionwas increased by H-Ras, and the treatment with
BLT2 inhibitor LY255283 or depletion of BLT2 using a BLT2-speciﬁc
small interfering RNA (siBLT2) greatly reduced the morphological
alterations and invasiveness of MCF-10A/Hras cells in response to
TGFb treatment. The induction of BLT2 expression in MCF-10A
cells showed a marked increase in invasiveness upon TGFb
treatment. This study clearly shows that Ras controls the
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expression of BLT2, which responds to TGFb treatment to promote
the adoption of the mesenchymal phenotype and invasion [104].
Various studies have shown that TGFb and Ras cooperate to
induce invasion. In the intestinal epithelium, the loss/inactivation
of TGFbR2 or expression of Kras alone did not result in neoplasia.
However, the combination of both lead to colorectal neoplasms
and eventual metastasis which were mediated through EGF [105].
Loss of Smad4 and the presence of oncogenic K-Ras can also induce
expression of MMP9 and urokinase plasminogen activator (uPA),
through the EGFR/NF-kB pathway, which contributes to the
invasive phenotype of cancer cells through activedegradation of
the extracellular matrix (ECM), liberating the cells from cell–cell
interactions and enabling extravasation from the primary
site [106].
In summary, there is growing evidence of crosstalk between Ras
and TGFb pathways at various levels in cell signaling cascades
leading to varying outcomes that can manipulate the EMT and
promote metastatic phenotypes.
5.1.3. JNK MAPK pathway
The c-Jun N-terminal kinase (JNK) cascade regulates various
transcription and non-transcription factors in response to external
stimuli and has been implicated in several biological processes
including cell proliferation, apoptosis and tumor development. The
TGFb system has the ability to autoregulate its own expression via
the JNK pathway making it an important pathway in cancer
development. TGFb treatment rapidly increased JNK activity
(within 5–10min) and induced up-regulation of urokinase
plasminogen activator receptor (uPAR) by increasing the protein-
–DNA complex formation at the distal Activator Protein-1 (AP-1)
site in the uPAR promoter region [107]. TGFb, however, did not
affect JNK protein expression [107]. As TGFb can activate Ras
within 3–6min of TGFb treatment, it is conceivable Ras may be
required for TGFb-mediated JNK activation.
JNKs, like Erk, are a third layer of MAPK cascade activated by
upstream MKKs—MKK4 and MKK7. The rapid Smad-independent
activation of JNK through TGFb is achieved speciﬁcally through
MKK4–TGFb-activated kinase 1 (TAK1) axis [108,109]. Further
upstream, tumor necrosis factor-receptor-associated factor 6
(TRAF6) associates with TGFbR2 and TGFbR1 through its
c-terminal TRAF domain to activate TAK1 in a receptor kinase-
independent manner. Yue et al. also reported that TGFbR2 is
required for TGFb-mediated activation of JNKwhich is required for
up-regulation of uPAR, suggesting a complex crosstalk between
these pathways [107]. Initially, it was thought that TRAF6 can only
directly interact with TGFbR2. However, the activation of
TGFbR2 occurs upon homodimer formation and TGFbR1 is
activated by TGFbR2. This suggests that TRAF6 binds to either
the active homodimer of TGFbR2 or the hetero-complex of
TGFbR2 and TGFbR1 [108]. Furthermore, TGFbR1 has a
TRAF6 binding motif (basic residue-X-P-X-E-X-X-aromatic/acidic
residue) and the TGFbR1–TRAF6 interaction is required for
TRAF6 autoubiquitylation and subsequent activation of
JNK/p38 pathways via TAK1 [109]. TRAF6 with the help of TGFb
induces Lys63-linked polyubiquitination of TGFbR1, which pro-
motes cleavage of the intracellular domain (ICD) of TGFbR1 by
TNF-alpha converting enzyme, in a PKCz-dependent manner [110].
The ICD of TGFbR1 can then translocate into the nucleus, where in
association with transcriptional regulator p300 it promotes
invasion by inducing the expression of Snail,MMP2 and p300
genes [111].
The TRAF6–TAK1–JNK cascade, in conjunction with the Smads,
is known to regulate TGFb-mediated apoptosis and EMT [109,112]
suggesting a close link between these cellular responses.
Yamashita et al. showed that TRAF6 and TGFb-mediated apoptosis
and EMT were abrogated when TRAF6 expression was knocked
down [108]. A similar effect was observed with knock down of
Smad3 expression. Interestingly, TAK1 also mediates
TGFb-induced signaling by phosphorylating the Smad3 linker
region (pSmad3L), a feature that is also observed in CRC [113].
pSmad3L can translocate into the nucleus and regulate gene
expression to mediate the development of an invasive phenotype
of cancer. TGFb can also activate JNK as part of an accessory
pathway, as shown by Ventura et al., who demonstrated that JNK-
deﬁcient ﬁbroblasts caused a signiﬁcant increase in expression of
TGFb1 and TGFbR1 and decreased the expression of TGFbR2 and I-
Smads [114], suggesting that JNK deﬁciency may cause autocrine
signaling of TGFb through a positive feedback loop. Freudlsperger
et al. [115] have shown that Smad7 and TAK1 mediate TGFb and
nuclear factor-kB (NF-kB) crosstalk in head and neck cancers.
TAK1 further enhances the activation of NF-kB through TGFb.
Treatment of head and neck squamous cell carcinoma (HNSCC)
lines with TGFb1 induced the phosphorylation of TAK1 along with
NF-kB family member RELA (p65). RELA and TGFb activation
induced Smad7 expression that preferentially suppressed
TGFb-induced Smad and NF-kB reporters leading to malignant
phenotype in HNSCC [115]. Additionally, the ability of Smad7 to
interact with TGFbR1 using two modes—a three-ﬁnger-like
structure in the MH2 domain and a basic groove in the
MH2 domain, in contrast to only one mode for Smad6, the other
I-Smad [116], suggests a dual role for Smad7: inhibition of TGFb-
Smad signaling and promotion of TGFb-induced activation of JNK
and p38 MAPK pathways.
The cooperation of Erk and JNK has been shown to jointly
increase the expression of a key late stage molecule, fascin1 in
gastric cancer, which promoted TGFb-mediated invasion and
metastasis [91]. Fascin1 expression was ablated by 75% when
treated with the JNK and Erk speciﬁc inhibitors, SP6001125 or
PD98059 respectively [91]. In addition to gastric cancer, a recent
study byHerbest et al. reported increased fascin1 expression in late
stage CRC was induced by b-catenin, an integral member of the
Wnt signaling pathway, that has been associated with
TGFb-mediated crosstalk during cancer [117].
5.1.4. p38 MAPK pathway
The p38 MAPK pathway is often activated by various stress
responses such as heat shock, osmotic shock and hypoxia leading
to diverse roles in cell proliferation, differentiation, survival and
migration in different cell types. It is unsurprising, therefore, that
p38 MAPKs have been implicated in cancer development [78].
p38 signaling is required for cell migration and metastasis in both
CRC and breast cancer [118,119]. As for JNKs, p38 MAPKs are
activated by MKKs through autophosphorylation: speciﬁcally by
MKK3 and MKK6 and sometimes by MKK4 [108,109]. Rapid Smad-
independent activation of p38 MAPKs is achieved through a
TAK1 and TRAF6 module [108,109] (Fig. 2). Knockdown of
TRAF6 inhibited TGFb-mediated EMT [108]. TGFb-induced activa-
tion of TRAF6-TAK1-JNK/p38 pathways has been implicated in cell
death, cell proliferation and EMT [110]. In breast cancer, ubiquitin-
conjugating enzyme Ubc13 was shown to control metastasis
through the TAK1-p38 MAPK pathway by activation of MEKK1 and
TAK1 [119]. Silencing of Ubc13 resulted in decreased
TAK1 phosphorylation, and the silencing of TAK1 or p38a resulted
in a dramatic decrease of lung metastasis in a mouse model [119].
Wu et al. also showed that the using the p38 inhibitor, SB203580,
resulted in decreased metastasis indicating that p38 inhibitors can
be used as potential treatment for established breast cancers [119].
Saﬁna et al. using MDA-MD-231 breast cancer cells, have showed
that TGFb-mediated TAK1 regulates MMP9 expression which
involves NF-kB signaling, similar to K-Ras. The TAK1-NF-kB-
MMP9 pathway as a whole, contributes to TGFb-mediated
metastasis [120]. p38 is also known to regulate cell invasion
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through up regulation of MMP2 in prostate cancer [110,121]. The
blockade of p38 MAPK activity using speciﬁc inhibitors, or by
genetic alterations or cancer therapies like 5-ﬂuorouracil, leads to
cell cycle recovery and induction of autophagic cell death [118,122].
Activation of Smads is an important cellular response for
TGFbRs. Cells with mutated TGFbR1 that are defective in Smad
activation showed an increase in p38 MAPK signaling response to
TGFb1, but did not induce EMT [123]. However, cells lacking the
cytoplasmic domain of TGFbR2 did not block TGFb-mediated
p38 MAPK activation, resulting in integrin avb1 mediated EMT
[124]. This conﬁrms that TGFbR2 is important for TGFb-mediated
EMT through the p38 MAPK cascade. The phosphorylation of
TGFbR2 tyrosine (Tyr248) in the cytoplasmic domain by Src
recruits Grb2 and Shc to TGFbR2, which associates these adapter
proteins with p38 MAPK activation [125]. Galliher-Beckley and
Schiemann also showed that Grb2 binding to Tyr248 of TGFbR2 is
required for TGFb-mediated mammary tumor growth and
metastasis [126]. Northey et al. showed that ShcA expression
and phosphotyrosine-dependent signaling are essential for
TGFb-mediated cell motility and invasion [127]. Galliher-Beckley
and Schiemann, and Northey et al. also showed that loss, or
reduced expression, of ShcA and/or Grb2, or mutations in their
phosphorylation sites, no longer promoted TGFb-mediated
migration, invasion, or EMT [126,127]. Rather than the “standard”
TGFb-mediated activation of p38 through MKK3 and MKK6, the
possible phosphorylation of TGFbR2 at Tyr248 has the potential to
drive Shc and Grb2 through an alternative pathway that is required
for TGFb-mediated tumor growth and metastasis. This secondary
activation of p38 through a pathway that would normally activate
Erk/JNK compounds the complexity of TGFb crosstalk with MAPK
pathways in cancer.
5.2. Wnt signaling cascade
Along with numerous other transcriptional regulators such as
the ﬁbroblast growth factors (FGF) and Forkhead transcription
factor families, the interplay betweenWnt and TGFb signaling is a
feature of gut development and endoderm formation [128]. More
recently, genome-wide association studies have found that both
the Wnt and TGFb pathways are active in lung cancer [129] and
breast cancer cells [130]. It has previously been proposed that
crosstalk between the Wnt and TGFb pathways may be more
extensive than suggested, especially in the context of malignancy
and/or the EMT [128]. This crosstalk may be occurring at several
points along the network, notably in the migration of cells as
witnessed in cancer and also ﬁbrosis [131,132].
Several studies have demonstrated the role of Smads, with
initial studies on homeobox gene promoters showing that TGFb
mimics the effects of Wnt signaling on b-catenin, leading to cell
cycle arrest through interactions with Smad7 [133]. Axin, a
negative regulator ofWnt signaling has also been shown to interact
with Smad3 as a putative adaptor, enhancing the efﬁciency of TGFb
signaling [134]. Wnt and FGF regulate the phosphorylation of the
Smad4 linker region through glycogen synthase kinase-3 (GSK3) in
the canonical MAPK/Erk site (PxTP) [128]. This phosphorylation
event did not occur when HaCaT immortalized, human keratino-
cyte cells were treated with the MEK-speciﬁc inhibitor
U0126, demonstrating the requirement of MAPK activity for
GSK3-induced Smad4 phosphorylation [128]. MAPK/FGF andWnt/
GSK3 mediated phosphorylation is required for the polyubiquiti-
nation and degradation of Smad4 through E3 ligase b-TrCP
[128,135,136]. As stated by Demagny et al., the MAPK/Erk and
GSK3 trigger the formation of a phosphodegron bound by the
E3 ligase b-TrCP, resulting in the polyubiquitination of Smad4.
Demangy et al. also showed that treatment of cells expressing the
TGFb-speciﬁc reporter CAGA12-luciferase with Wnt3a or
FGF2 alone did not affect TGFb signaling activity. However, the
addition of both increased TGFb signaling activity, indicating the
involvement of GSK3 [128]. This demonstrates that FGF is also
required for TGFb and Wnt crosstalk which is enhanced by
activation of MAPK signaling. It is important to note that another
study reported that TGFb suppressesb-catenin/Wnt signaling and
enhances cell adhesion in CRC in a Smad4-independent manner
[132]. A similar study to that of Demangy et al., reported the
ability of TGFb to promote the EMT and invasion in a p38
MAPK/b-catenin/peroxisome proliferator-activated receptorg-de-
pendent manner in non-small cell lung cancers [137].
Numerous canonical and non-canonical Wnt signaling proteins
have also been shown to act as co-factors of TGFb signaling,
including, but not limited to, Snail, Twist, b-catenin and AP-1 by
either activating or suppressing the activity of various Smads (for a
comprehensive review refer to [138]). These interactions have not
been directly observed in CRC, though this crucial link may bridge
the gap between these two signaling pathways (i.e., that of Notch,
Wnt, and TGFb/Activin signaling) which is in part mediated by the
interactions of Dll1 with Smad2/3 and Tcf4 at the promoter sites
[139]. A further point of interaction between the Wnt and TGFb
signaling pathways involves the regulation of the same genes
independently or cooperatively. Both regulate Lef1/Tcf, which are
canonical proteins involved in the EMT [140]; gastrin, a promoter
of gastrointestinal cancers [141]; BAMBI, the pseudoreceptor
involved in TGFb signaling regulation in CRC [142]; and
importantly Snail1 and Snail2, both of which are acknowledged
as key switches that initiate the EMT in cells, and have been
implicated in CRC [143–146]. Other canonical Wnt signaling
molecules such as Twist and KLF8 have also been shown to be
regulated by TGFb [138].
Several other proteins involved inWnt and TGFb signaling have
been shown to be perturbed in CRC cell lines and tissues, including
Pitx2 [147], a homeodomain transcription factor, and ECM
transition remodeling proteins such as heparin-degrading endo-
sulfatases, sulfatase 1 (SULF1) and sulfatase 2 (SULF2). Recent
studies have shown that FOXQ1, a member of the forkhead
transcription factor family, can promote TGFb expression and the
EMT through crosstalk between the Wnt and TGFb signaling
pathways [71,148]. Fan et al. [148] showed that silencing
FOXQ1 decreased cell migration and invasionwhichwas supported
by Peng et al. [71]. Interestingly, treating the cells with
TGFb1 increased FOXQ1 gene expression resulting in TGFb-
mediated the EMT within 4-days, that was suppressed upon
silencing FOXQ1 expression [148]. A similar outcomewas reported
by Peng et al. wherein treatment of CRC cells with TGFb1 increased
FOXQ1 expression and promoted migration and invasive potential.
They also demonstrated that FOXQ1 suppression by siRNA
decreased the invasive and angiogenic potential and resistance
to chemotherapy drugs. Peng et al. further showed that FOXQ1 is
overexpressed in CRC tissues and correlates with CRC stage [71].
Indeed, other recent studies further support the fact that
overexpression of FOXQ1 induces the EMT in various cancers
[149–151] and has been shown to be a direct Wnt target in CRC
[152].
The overall picture regarding Wnt and TGFb signaling is that of
a highly interconnected system of activators and repressors that
serve to maintain cell proliferation and migration. The details of
theWnt and TGFb pathways continue to be elucidated, with novel
players such as FOXQ1 continually changing the models of
potential crosstalk between these two pathways. Sufﬁce it to
say that in cancers, particularly CRC, the involvement of both these
pathways is crucial not only for ECM degradation but also for
metastasis as evidenced by the involvement of APC in over 60% of
loss of heterozygosity (LOH) positive CRC cases [153,154]. A
detailed analysis of this crosstalk system is beyond the scope of this
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current review. However, there is extensive evidence indicating
that such crosstalk strongly inﬂuences the EMT and metastasis.
6. Genetic alterations in TGFb signaling components
Various intracellular signaling pathways, including the ones
described above, are frequently dysregulated in CRC. Almost 75% of
CRC cell lines are resistant to TGFb-mediated growth inhibition
due to the loss ormutation of one ormore components of the TGFb
signaling pathway [155,156]. A detailed review of the genetic
alterations of TGFb signaling components speciﬁcally in CRC has
been published by Wu et al. [158].
Genetic alterations of TGFbR2 are the most common mecha-
nism leading to the loss of TGF-b signaling in CRC. Inactivation of
TGFbR2 frequently occurs due to microsatellite instability (MSI),
resulting from DNA mismatch repair defects, causing nucleotide
additions or deletions in simple repeated sequences, or micro-
satellites in the genome [156,159]. Additionally, impairment of
TGFb-mediated anti-proliferative responses due to mutation of
TGFbR1 has also been observed [160]. However, the presence of a
common polymorphic variant TGFbR1*6A has been shown to
increase the risk of CRC and several other cancers [161,162].
Genetic polymorphisms of TGFb1 have also been associated
with colorectal neoplasia, although meta-analyses of particular
alleles demonstrated inconclusive correlation with a single
mutation [163,164]. The mostly widely studied TGFb1 genetic
alterations are TGFb1 509 C >T, +869 T >C, +915 G>C, and
800 G>A [164]. Meta-analysis by Liu et al., has shown that the
TGFb1 509 C> T, +869 T >C, +915 G>C, and 800 G>A
polymorphisms are not associated with colorectal adenoma, but,
C allele of509 C> T and A allele of800 G>A are associated with
increased CRC risk [164]. In addition, the 509 C> T has been
reported to be associated with increased risk of developing CRC by
Wang et al. [165] and decreased risk of CRC by Liu et al. [163].
Mutation or deletions in Smad genes can also be an important
factor during tumor development. Most commonly mutations are
seen on Smad4 and Smad2, due to allelic loss or LOH that has been
demonstrated in up to 60% of CRCs. Mutations in Smad4 gene
(16–25%) and Smad2 gene (6%) have been associated with CRC.
Smad4 and Smad2 genes along with tumor suppressor gene DCC
(deleted in colorectal cancer) are localized at chromosome 18q21
[166]. Smad4 mutations are found in about 11% of familial
adenomatous polyposis and 11% of hereditary non-polyposis
colorectal cancer [157,167] syndromes. Smad2 mutations occur in
the MH1 or MH2 domains of the molecule affecting the
phosphorylation, nuclear translocation, and/or decreasing pro-
tein stability ultimately disturbing TGFb signaling. Similar
mutations or LOH of Smad3 gene (located on 15q21–q22) were
reported in a human CRC cell line (SNU-769A) [160]. A later study
using 36CRC cell lines and 744 primary CRC patient tumor biopsy
samples concluded that approximately 4% of them carried
mutations in the Smad3 gene [168]. Concurrently, the loss of
Smad3 expression in gastric cancer tumors/cells has been
associated with high susceptibility to cancer [169]. This multitude
of genetic mutations in TGFb signaling components, and the
signaling crosstalk with various pathways during the develop-
ment of cancer, enhance its ability to invade and metastasize to
various organs, resulting in decreased 5-year survival.
7. Conclusion
TGFb signaling plays major roles in regulating normal cell
growth, although various cancer studies have suggested that
canonical TGFb signaling is unfaithful. It is promiscuously involved
in intracellular signaling crosstalk with various pathways, includ-
ing, but not limited to, Erk, JNK, Ras, p38 and Wnt. TGFbRs play a
crucial role in non-canonical signaling which collectively result in
changes that drive cancer progression and metastasis. The poorly
understood Janus-like nature of TGFb in cancer is likely the
product of these interrelations and correlations that do not have
simply one single signature. This may explain why understanding
it remains elusive. This is potentially how awidely accepted tumor
suppressor in benign cells “switches” to promote cancer progres-
sion. Understanding this switch to a tumor-promoting outcome
remains an important question that is likely to be answered in the
minutiae of less established interactions.
This review has explored many possible avenues of TGFb
crosstalk and their consequences in cancer. It is crucial to note that
almost no TGFb signaling component has a single function. For
instance the dual kinase activity of TGFbR1 and the two modes of
Smad7 interaction with TGFbR1 further add to complexity of
TGFb-crosstalk that is already poorly understood. This complex
crosstalk in CRC, we propose, can be investigated by implementing
a combination of sophisticated informatics, -omics technologies
and in vivo studies in a spatio-temporal manner, coupled with
larger protein tracking and interaction studies. Emerging multi-
plexed technologies such as SOMAmer1 [170], proximity exten-
sion assays [35,171] and/or SureFire1 assays [172] will be crucial in
the coming years to perform more elaborate experiments in order
to elucidate complex cell signaling behaviors within a matrix of
different pathways and the crosstalk between them. It is crucial to
remember that in cancer and various diseases, we cannot study
these pathways in isolation but instead must transition into a
matrix-oriented systems approach that more comprehensively
models the spatio-temporal ramiﬁcations of signaling activities
within the complexity of living cells and tissues. A better
understanding of four-dimensional biology is essential to identify
in vivo signaling signatures that are of clinical relevance,
facilitating the development of more effective, targeted therapeu-
tics to combat a global health burden.
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